Mycophenolic Acid
NDC Package 71151-030-01

11-digit billing NDC: 71151003001

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Mycophenolic Acid is delayed-release tablets are indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant.Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant.Mycophenolic acid delayed-release tablets are to be used in combination with cyclosporine and corticosteroids. Marketed by Airis Pharma Private Limited, this product is identified by NDC 71151-030 and is authorized under FDA application ANDA217031.

Identification & Billing

NDC Package Code
71151-030-01
Package Description
120 TABLET, DELAYED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
71151003001
RxNorm Crosswalk
  • RxCUI: 485020 - mycophenolic acid 180 MG Delayed Release Oral Tablet
  • RxCUI: 485020 - mycophenolic acid (as mycophenolate sodium) 180 MG Delayed Release Oral Tablet
  • RxCUI: 485023 - mycophenolic acid 360 MG Delayed Release Oral Tablet
  • RxCUI: 485023 - mycophenolic acid (as mycophenolate sodium) 360 MG Delayed Release Oral Tablet

Clinical Specifications

Proprietary Name
Mycophenolic Acid
Dosage Form
-
Usage Information
Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant.Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant.Mycophenolic acid delayed-release tablets are to be used in combination with cyclosporine and corticosteroids.

Regulatory & Marketing

Labeler Name
Airis Pharma Private Limited
FDA Application #
ANDA217031
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-05-2024
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71151-030-01 identifies a specific commercial package of 120 tablet, delayed release in 1 bottle of Mycophenolic Acid, labeled by Airis Pharma Private Limited. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Airis Pharma Private Limited on January 05, 2024. The current certification is valid through December 31, 2025.

How is this Airis Pharma Private Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71151003001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71151-030-01
11-Digit CMS (5-4-2)
71151-0030-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.